All GLG News Analyses Filed Under: Laboratory Operations

Ken PowellPresidentGenesis Business Development, LLC

Will Quest Acquire Vermillion?

November 20, 2009

Analysis of:Why Quest Will Acquire Vermillion | www.genomeweb.com

Quest Diagnostics has had a known relationship with Vermillion.  Now that Vermillion has received FDA approval for its OVA1 in vitro diagnostic multi-variant index assay (IVDMIA) and Quest has an exclusive three year marketing license and a 17% investment in the company plus additional loans, acquisition of Vermillion could make sense for both companies.

Ken PowellPresidentGenesis Business Development, LLC

Roche Receives H1N1 FDA Emergency Use Authorization

November 16, 2009

Analysis of:Roche Gets FDA EUA for H1N1 Test Kit | www.genomeweb.com

Roche has received an Emergency Use Authorization from the FDA for its RealTime ready Influenza A/H1N1 Detection Set.  The new H1N1 assay is run on its MagNA Pure LC platform for nucleic acid isolation and its LightCycler 2.0 system for real-time PCR applications.  Roche, the worldwide clinical diagnostics leader should have an advantage in the H1N1 market segment.

Ken PowellPresidentGenesis Business Development, LLC

Sequenom Sued by Shareholders

November 14, 2009

Analysis of:Sequenom Shareholders Sue Company, Officials over SEQureDx Data Mishandling | www.genomeweb.com

The Sequenom sage appears endless.  Following the "mishandling of data" involving the company's Down's syndrome test, termination of company executives, investigation by the NASDAQ , the SEC and the US Attorney for the Southern District of California, Xenomics lawsuit against Sequenom seeking up to $300 million in damages, Sequenom shareholders have filed a suit against the company and several individual current and former executives .  The news continues to mount and none of it is good.

Ken PowellPresidentGenesis Business Development, LLC

Epigenomics Reports Excellent 3Q Returns

November 12, 2009

Analysis of:Epigenomics Nearly Quadruples Sales in Q3 | www.genomeweb.com

Germany based Epigenomics posted stellar Q3 financial results and reduced net loss by 8%.  According to the company, the increase comes from existing collaborations, new partnerships, and license agreements

Ken PowellPresidentGenesis Business Development, LLC

New Sample Prep Company

November 12, 2009

Analysis of:Life Technologies to Buy Biotrove, Which Will Form Mass Spec Sample Prep Company | www.biotrove.com

Following on Life Technologies' (NASDAQ: LIFE) acquisition of Biotrove, Biotrove announced in a separate release that it will form a subsidiary for a sample handing company for mass spectroscopy systems.  This could be the real opportunity for future growth.

Ken PowellPresidentGenesis Business Development, LLC

Consolidation Continues in Life Sciences

November 11, 2009

Analysis of:Qiagen Acquires SABiosciences for $90M | www.genomeweb.com

Qiagen (NASDAQ: GQEN) has entered into a definitive agreement to acquire privately held SABiosciences for $90 million dollars.  Meanwhile, Life Technologies has entered into a definitive agreement to acquire, the manufacturer of the OpenArray high-throughput gene expression and genotyping system.  Yesterday's announcements are more examples of the high level of consolidation activity occurring in the wide open life sciences space.

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC)

What is potential future for Sequenom in prenatal testing.

November 9, 2009

Analysis of:So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com

The historic but minimally supported enthusiasm for the Sequenom prenatal test has previously been reported in this space previously. Even in the absence of data retractions, leading to termination of much of senior management, problems in the rollout of the product should have been anticipated.Remarkably, this article asserts that industry insiders remain optimistic about the development of a successful diagnostic product.

Ken PowellPresidentGenesis Business Development, LLC

Quest Diagnostics to Offer New Colorectal Cancer Test

November 9, 2009

Analysis of:Quest to Offer Septin9 Colorectal Cancer LTD 'Later This Year' | www.genomeweb.com

Quest Diagnostics senior spokesperson Jay Wohlgemuth said that Quest plans to launch a new Laboratory Developed Test (LDT) for colorectal cancer based on Epigenomics’ mSEPT9 DNA-methylation biomarker.  Many companies have searched for a blood-based marker as an effective diagnostic alternative to colonoscopy, which would encourage the 90 million adults over 50 to be screened for colorectal cancer.

Ken PowellPresidentGenesis Business Development, LLC

What's Next for Sequenom?

November 7, 2009

Analysis of:So Where Does Sequenom’s Prenatal Play Currently Stand? | www.genomeweb.com

Those following the Sequenom saga continue their seemingly endless attempts to decipher a clear direction for the company.  Amid data mishandling, executive terminations and a stunning $300 million dollar lawsuit, there could be options for the company to revive and survive.

Robert BoorsteinAssociate Professor, PathologyNEW YORK UNIVERSITY (INC)

Potential impact of large clinical trial on Liquid based cytology market

November 5, 2009

Analysis of:Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com

The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology has essentially replaced conventional Pat testing in this country, and it is unlikely that there is evidence that would reverse this. However, it is possible such studies will put downward pricing pressures on reimbursments, both in amounts and frequencies.

Page : 12345678910Next1 to 10 of 252